Blood Marker Could Allow CTE Diagnosis in Living Patients
US researchers found a blood protein fragment that tracks advanced chronic traumatic encephalopathy. The test is not validated yet and misses the early stage.
Contact sport has an unsolved problem: chronic traumatic encephalopathy cannot be confirmed in a living person. A small blood study now points to a possible way around that, but only for advanced cases.
Why sport watches this field
CTE is a degenerative brain condition. Repeated blows to the head cause it, and it is especially common in collision and contact sports such as American football, rugby and football.
In one recent study of nearly 400 donated NFL brains, 93.5% showed signs of the disease. Over 350 NFL players have received the diagnosis after death. Among them are hall of fame center Mike Webster, Junior Seau, who played for 20 years and reached two Super Bowls, and Frank Gifford, a former MVP and prominent broadcaster.
Rugby faces court cases. A number of former union and league players are still pursuing legal action, and some of them are alive and carry a diagnosis of Traumatic Encephalopathy Syndrome. England World Cup winner Steve Thompson is among them. Boxer Ricky Hatton received a mild CTE diagnosis only after he died.
Football has turned to prevention. Earlier this year the Professional Footballers' Association recommended that professionals head a ball no more than 10 times a week in training. For children under 12 it advised no heading at all.
A protein fragment in blood
Until now the only route to a CTE diagnosis has been examining brain tissue after a person dies. That is why a blood marker draws attention.
Scientists at Washington University School of Medicine in St Louis identified a protein fragment called eMTBR-tau243. It was already known to be raised in Alzheimer's disease. They report it also rises in other diseases built on the same kind of harmful protein clumps, CTE among them. The findings appeared in JAMA Neurology.
"We are potentially opening a new door for diagnosing and treating CTE in living patients," said Kanta Horie, co-senior author of the study.
Where the test falls short
The team tested blood from 11 people whose CTE had been confirmed at autopsy. Their levels of the fragment were higher than those of healthy people, and the levels rose as the disease grew more severe. Advanced CTE could be told apart from healthy samples with high accuracy.
Early-stage CTE was another matter. The test could not reliably identify it.
Co-author Chihiro Sato, a neuroscientist, was frank about the limits. "This is not going to be a standalone biomarker," she said.
Her example was a person with a history of repeated head injury who tests negative for Alzheimer's while the biomarker comes up. In that case, she said, the explanation might be CTE.
The test has not been validated for diagnosing CTE. The scientists say large confirming studies could let doctors use a blood test like this to watch people at risk. It could also allow trials of drugs that might help the condition.
Source: The Guardian